PaxMedica EBIT

The latest EBIT for PXMD is $-16M as of June 2024. That compares with $-15M in the prior-year period — down 3.8% year over year. That is above the sector sector average of $-63M. Investors often review this figure alongside PaxMedica's historical trend and sector peers before judging valuation or financial health.

Over the past year, PXMD's EBIT moved from $-15M to $-16M — a 3.8% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PaxMedica's operating scale or balance-sheet position.

Against its sector companies, PXMD currently prints $-16M for EBIT, while the sector average sits near $-63M. That is roughly 75.0% above the sector mean. Large gaps often invite a closer look at PaxMedica's growth, margins, and balance sheet.

A EBIT figure of $-16M for PXMD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $-63M. Explore the charts below for those layers of context.

After noting PXMD's EBIT ($-16M), review year-over-year change from $-15M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.